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ValvotomyAbstract Percutaneous mitral balloon valvotomy (MBV) was introduced in 1984 by Inoue who
developed the procedure as a logical extension of surgical closed commissurotomy. Since then,
MBV has emerged as the treatment of choice for severe pliable rheumatic mitral stenosis (MS).
With increasing experience and better selection of patient, the immediate results of the procedure
have improved and the rate of complications declined. When the reported complications of MBV
are viewed in aggregate, complications occur at approximately the following rates: mortality
(0–0.5%), cerebral accident (1–2%), mitral regurgitation (MR) requiring surgery (0.9–2%). These
complication rates compare favorably to those reported after surgical commissurotomy. Several
randomized trials reported similar hemodynamic results with MBV and surgical commissurotomy.
Restenosis after MBV ranges from 4% to 70% depending on the patient selection, valve morphol-
ogy, and duration of follow-up. Restenosis was encountered in 31% of the author’s series at mean
follow-up of 9 ± 5.2 years (range 1.5–19 years) and the 10, 15, and 19 years restenosis-free survival
rates were (78 ± 2%) (52 ± 3%) and (26 ± 4%), respectively, and were signiﬁcantly higher for
patients with favorable mitral morphology (MES 6 8) at 88 ± 2%, 67 ± 4% and 40 ± 6%, respec-
tively (P< 0.0001). The 10, 15, and 19 years event-free survival rates were 88 ± 2%, 60 ± 4% and
28 ± 7%, respectively, and were signiﬁcantly higher for patients with favorable mitral morphology
92 ± 2%, 70 ± 4% and 42 ± 7%, respectively (P< 0.0001). The effect of MBV on severe pul-
monary hypertension, concomitant severe tricuspid regurgitation, left ventricular function, left
atrial size, and atrial ﬁbrillation is addressed in this review.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Mitral stenosis is a progressive disease that leads to heart failure
and is ﬁnally fatal unless mechanical intervention enlarges the
134 M.E. Fawzymitral valve oriﬁce to permit adequate cardiac output at a toler-
able left atrial pressure. Starting over 50 years ago a variety of
surgical techniques were developed; ﬁrst closed commissurot-
omy followed by open commissurotomy after the introduction
of the cardiopulmonary bypass.1,2 Mitral balloon valvotomy
was introduced in 1984 by the Japanese surgeon Inoue, who
developed the procedure as a logical extension of surgical closed
commissurotomy.3 Since then, MBV has emerged as the treat-
ment of choice for severe pliable rheumatic mitral stenosis.
The mechanism by which both procedures reduce stenosis is
the same and involves mechanical dilatation of fused
commissures.4 Several randomized trials reported similar
hemodynamic results with balloon valvotomy and surgical
commissurotomy. However, periprocedural complications in
surgical patients were somewhat higher.5–8 Both forms of com-
missurotomy eliminate the risks common to prosthetic valves,
which include primary valve failure, thromboembolism, and
endocarditis. The purpose of this review is to summarize the
immediate and long-term results up to 19 years of MBV, its
complications, and elucidate the effect of MBV on severe pul-
monary hypertension, concomitant severe tricuspid regurgita-
tion, left ventricular function, left atrial size, and atrial
ﬁbrillation.
2. Techniques
The transseptal technique is the most common technique used
to perform MBV. The technique consists of advancing a cath-
eter over the wire across the interatrial septum after transseptal
puncture, enlarging the opening and advancing one large bal-
loon (Inoue balloon) or two smaller balloons (double-balloon
technique) across the mitral oriﬁce and inﬂating them within
the oriﬁce. Although acute and short-term outcomes differ lit-
tle between these two techniques,9,10 complications such as
death, left ventricular perforation, and stroke appear to be less
common with the Inoue balloon. The multiple advantages of
the Inoue balloon, include low proﬁle of the device, the elimi-
nation of the stiff guide wire (minimizing the risk of LV perfo-
ration), easy maneuverability, and the stepwise dilation
(gradual increase of balloon size on sequential inﬂations).11
3. Echocardiographic evaluation
Echocardiography is the mainstay of the noninvasive evalua-
tion of mitral stenosis. The transthoracic echocardiography
provides an evaluation of the valvular apparatus, mitral valve
area (MVA), left atria dimension, and associated valve lesions.
Doppler echo provides hemodynamic evaluation including
mean mitral gradient, MVA, assessment of concomitant tricus-
pid regurgitation (TR) and estimation of pulmonary artery
pressure. The morphologic evaluation of the mitral valve is
semiquantilated using echocardiographic score (echo score).
The scoring system evaluates leaﬂet thickening, mobility,
calciﬁcation, and subvalvular involvement on a scale of 0–4,
as described by Wilkins et al.12 The mitral valve morphology
is considered favorable if the mitral echocardiographic score
(MES) is 68. Transesophageal (TEE) echo should be per-
formed before MBV for patients with atrial ﬁbrillation or prior
history of systemic embolism or very obese patient where the
left atrium was not properly visualized. We do not recommend
TEE as a routine procedure before MBV.134. Results
4.1. Immediate hemodynamic results
The left atrial pressure, mean mitral gradient, and pulmonary artery
systolic pressure decreased signiﬁcantly after MBV with a corre-
sponding increase inMVA. In theNationalHeart, LungBlood Insti-
tute Balloon Valvotomy Registry of 736 patients,14 the MVA by
echocardiographic assessmentwas 1.09± 0.29 cm2before the proce-
dure and increased to 1.8± 0.15 cm2 after the procedure. In the
author’s series, 547 consecutive patients13 the echocardiographic
MVA was 0.92 ± 0.17 cm2 before the procedure, and in-
creased to 1.95 ± 0.29 cm2 after the procedure. A signiﬁcant
inverse relationship was found between the echo score and
post-procedure MVA where mitral valve morphology was
found to be a strong predictor of post-procedure mitral open-
ing.12,15 However, good results could also be obtained in cases
with relatively high echo score.4.2. Complications of balloon mitral valvotomy
In general, MBV is a safe procedure with high success rate,
particularly if the patients chosen have optimal valve morphol-
ogy as determined by echo score. When the reported rates of
complications of MBV are viewed in aggregate, complications
appear to occur at approximately the following rates: mortal-
ity (0–0.5%), cerebrovascular accident (CVA) (0.5–2%), car-
diac tamponade (0.7–1%), mitral regurgitation requiring
surgery (0.9–2%), mitral regurgitation of some degree (15%),
and atrial septal defect detected by color Doppler (20–23%)
which, however, closes or decreases in size in most
patients.11,16,174.3. Long-term follow-up and predictors of restenosis and event-
free survival
4.3.1. Mitral restenosis
The restenosis rate after MBV has been reported as 39% at
7 years18 and was lower (31%) at 19 years in our younger pop-
ulation (mean age 31.5 ± 11 years)19 and was 20% in sub-
group of patients with MES 6 8. The actuarial freedom from
restenosis rates for this population were 78 ± 2% at 10 years,
52 ± 3% at 15 years, and 26 ± 5% at 19 years and were sig-
niﬁcantly higher for patients with optimal morphology echo
score 6 8, namely 88 ± 2% at 10 years, 67 ± 4% at 15 years,
40 ± 6% at 19 years (Fig. 1) . The predictors of being free
from restenosis were a low echo score (P< 0.0001) and
post-procedure MVAP 2.0 cm2.19–214.3.2. Event-free survival
Iung et al. reported an event-free survival (survival with free-
dom from redo MBV, MVR, cardiac death, NYHA functional
class III or IV) rate of 61% at 10 years in 528 patients with suc-
cessful PMBV (mean age, 49 years).21 Palacios et al. (879 pa-
tients with successful MBV mean age, 55 years) reported a
rate of 38% at 12 years for patients with echo score 68 and
22% for patients with echo score >8.22 Event-free survival
rates at 10, 15, and 19 years were 88%, 60%, and 28%, respec-
tively, in our relatively younger patients and were signiﬁcantly
Mitral balloon valvotomy, long-term results, its impact on severe pulmonary hypertension 135higher for patients with MES 6 8 (92%, 70%, 42%, respec-
tively; P< 0.0001). The predictors of event-free survival were
low echo score and baseline A.F (P< 0.0001 and P= 0.014,
respectively)19 (Fig. 2).
4.3.3. Regression of severe pulmonary hypertension
Pulmonary hypertension frequently complicates mitral stenosis
and may signiﬁcantly inﬂuence the clinical ﬁndings and prog-
nosis of this condition. The increase in pulmonary arterial
pressure is often out of proportion to the degree of left atrial
hypertension, reﬂecting a major increase in pulmonary vascu-
lar resistance.23,24 To elucidate the effect of MBV on severe
pulmonary hypertension, the author studied 559 consecutive
patients with severe MS undergoing successful MBV. Patients
were allocated to three groups on the basis of their pulmonary
artery systolic pressure (PASP) at cardiac catheterization prior
to MBV; group A (n= 345; 62%) had mild pulmonary hyper-
tension (PASP< 50 mmHg); group B (n= 183; 33%) had
moderate pulmonary hypertension (PASP 50–79 mmHg);
and group C (n= 31; 5%) had severe pulmonary hypertension
(PASPP 80 mmHg). Immediately following valvotomy, the
PASP normalized in group A, in group B and C, pulmonary
hypertension decreased slightly with further substantial regres-
sion occurring overtime (Fig. 3) and severe pulmonary hyper-
tension normalized over 6–12 months in patients with
successful PMBV and follow-up MVAP 2.0 cm2.25,26
4.3.4. Regression of signiﬁcant tricuspid regurgitation
Signiﬁcant tricuspid valve regurgitation (TR) is a common
ﬁnding in patients with severe MS and in the majority of cases,
it is functional, resulting from right ventricular and tricuspid
annular dilation caused by long standing pulmonary hyperten-
sion. Although earlier reports suggested that TR can resolve
once the diseased mitral valve is replaced,27,28 the results of la-
ter studies are contradictory.29,30 We and other investigatorsFigure 1 Freedom from restenosis by Kaplan–Meier estimates for al
represent patients alive and uncensored at each year of follow-up.demonstrated regression of signiﬁcant TR after successful
MBV in relatively young patients (mean age 25 ± 10 years)
with severe MS and concomitant signiﬁcant pulmonary hyper-
tension (70 ± 22 mmHg).31,32 On the other hand, Sagie et al.33
reported no regression of TR in relatively older patients (mean
age 57 ± 15 years) with severe MS and mild pulmonary hyper-
tension (46 ± 15 mmHg). We demonstrated that severe pul-
monary hypertension is a strong predictor of regression of
severe TR after MBV.31
4.3.5. Effect of mitral valvotomy on left ventricular function
In most cases of mitral stenosis, the left ventricular contractil-
ity is normal. However, in about one third of patients with mi-
tral stenosis left ventricular systolic function is reduced.
Preload reduction – caused by limited mitral inﬂow – and in-
creased afterload – precipitated by reﬂex vasoconstriction sec-
ondary to decreased cardiac output, act in concert to reduce
ejection performance.34 We have demonstrated normalization
of impaired LV systolic function after successful MBV in pa-
tients with severe MS.35
4.3.6. Effect of MBV on left atrial size
Signiﬁcant reduction of LA size following successful mitral
Valvotomy was demonstrated by several investigators.36–38
To demonstrate the effect of MBV on left atrial size, 205 con-
secutive patients (mean age 31 ± 11 years) were studied by the
author. LA size at baseline and at mean follow-up of
31 ± 21 months after successful MBV (post-procedure
MVAP 1.5 cm2, MR 6 214) was analyzed. LA anteroposte-
rior dimension decreased in 87% of the patients (from
48.7 ± 7 to 42 ± 6.6 mm; P< 0.0001) whereas in 13%, it re-
mained unchanged or even increased. Similarly, LA volume
was decreased in 93.5% of patients (from 92 ± 29 to
61 ± 24 cm3; P< 0.0001) whereas in the remaining 6.5% of
patients it remained unchanged or even increased. LA antero-l patients and for patients with MES 6 8. Numbers at the bottom
Figure 2 Kaplan–Meier event-free survival estimates (alive and free of redo MBV, MVR, NYHA III or IV) for all patients and for
patients with MES 6 8. Numbers at the bottom represent patients alive and uncensored at each year of follow-up.
Figure 3 Mean pulmonary artery systolic pressure estimated by Doppler echocardiography for groups A–C at baseline and at follow-up
over 12 months.
136 M.E. Fawzyposterior dimension returned to normal in 29.2% of patients in
sinus rhythm and in none of the patients with AF. Multiple lin-
ear stepwise regression analysis was used to identify predictors
of regression of LA size after MBV. The variables included in
the analysis were gender, age, baseline anteroposterior LA
dimension, baseline and post-procedure echo MVA, echo
score, and baseline AF. Only two of these variables (baseline
anteroposterior LA dimension and baseline AF) were shown
to be predictors of regression of LA dimension (P< 0.001).374.3.7. Effect of MBV on the incidence of atrial ﬁbrillation
We demonstrated a favorable effect of MBV on the long-
term incidence of chronic AF (8.9%) in patients with severe
MS39 in comparison with the historical controls (29%) of
patients with severe MS and similar baseline characteristics
who were not submitted to intervention.40 The predictors of
AF were age, large LA> 40 mm, small MVA (61.5 cm2) at
follow-up.39
Mitral balloon valvotomy, long-term results, its impact on severe pulmonary hypertension 1374.3.8. Comparison of mitral balloon valvotomy with surgical
commissurotomy
MBV is associated with less morbidity, shorter hospital stay,
avoidance of the discomfort and other problems associated
with thoracotomy, while the cost of surgery is at least twice
that of balloon Valvotomy in the United States.41 The imme-
diate results appear to be very similar to closed and open sur-
gical commissurotomy6,8 while operative mortality from closed
commissurotomy was 2.97%42 which was higher than that re-
ported after MBV (0–0.5%).14 The only long-term, though rel-
atively small (30 patients in each group), randomized study
comparing surgical closed, open, or percutaneous commissur-
otomy, has been reported by Farahat et al. in young popula-
tion with pliable, noncalciﬁed valves. The 7-year results were
better for open and percutaneous procedures than for closed
commissurotomy as assessed by a higher event-free survival
(93%, 90%, and 50%, respectively), better follow-up MVA
(1.8, 1.8, and 1.3 cm2) and lower restenosis rate (6%, 6%,
and 37%).8 In long-term surgical series Hickey et al. reported
on 103 patients with closed commissurotomy (mean age
38 years) event-free rate from mitral valve replacement of
78% at 10 years and 47% at 20 years.43 Rihal et al. reported
on 267 patients’ (mean age 43 years) event-free rate from
MVR 57% at 10 years and 24% at 20 years.44 In our series,
the combined event-free rates after MBV are 88% at 10 years,
60% at 15 years, and 28% at 19 years which were not worse
than those of surgical series.195. Conclusions
Mitral balloon valvuloplasty, which is the procedure of choice
in the treatment of rheumatic mitral stenosis, has excellent
immediate and long-term results in patients with favorable mi-
tral valve morphology but those with less favorable anatomy
may still have reasonably good hemodynamic and symptom-
atic relief. This technique is associated with less morbidity
and long-term results are better than the historical reported
surgical results. The long-term outcome can be predicted from
baseline clinical and valvular characteristics. MBV is safe and
effective when treating patients with MS and severe pulmonary
hypertension, the latter condition being normalized over
6–12 months after successful MBV. Severe TR regresses after
successful MBV in the presence of severe pulmonary hyperten-
sion. Severely impaired LV systolic function normalized after
successful MBV.Conﬂict of interest statement
The author of the manuscript claims no conﬂict of interest.References
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